You are here: Industry Insights > Bi

News List

Regenerative Medicine and Drug Development: The Intersection of Stem Cells and Biotech Nurah Ekhlaque
January 17, 2025
Explore how regenerative medicine and biotech are transforming drug development with stem cell therapies, personalised treatments, and innovative solutions.
HIV and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir David Orchard-Webb
January 07, 2025
HIV is a major worldwide health issue, producing substantial morbidity and mortality.HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
How to Source Safe and Effective Antibiotic APIs for Pediatric Formulations Saher Haider
December 09, 2024
Given children's unique physiological and pharmacokinetic characteristics, the development of pediatric antibiotic formulations requires stringent controls.
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors Yefenghong
October 18, 2024
Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
Decoding the Role of Synthetic Biology in Pharmaceuticals Neeta Ratanghayra
October 16, 2024
Recognized for its transformative potential, synthetic biology has emerged as a technology poised to revolutionize various industries, including pharmaceuticals.
Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .